Overview
Human papillomaviruses (HPV) are very common contagious viruses: approximately 70% of men and women will be infected during their lifetime. Vaccination, recommended since 2007 for girls and since 2021 for all young people aged 11 to 14 (with catch-up vaccination possible up to age 26), remains insufficiently followed. Today, only 40.7% of adolescents are vaccinated in France, and the Auvergne Rhône Alpes region remains below the targets (47.5% for girls and 12.3% for boys). This is still far from the national target of 80% vaccination coverage by 2030, while 6,400 new cases of HPV-related cancers are reported each year. The PIMCOP regional study aims to assess the impact of a primary prevention intervention, co-developed with stakeholders and implemented in middle and high schools, on the HPV vaccination rate at 6 months among 11-17 year olds.
Eligibility
Inclusion Criteria for children :
- Girl or boy, student at a public school participating in the study
- Aged 11 to 17
- Having received an information sheet about the study and having signed a declaration of non-objection
- Whose parents have also received an information sheet and have not expressed their non-objection
- Able to read, write, and understand French
- Affiliated with the SS or equivalent
Exclusion Criteria for children:
- children protected by the law
Inclusion Criteria for teachers :
- Male or female, teacher at a public school participating in the study and supervising a participating class
- Aged 18 or over
- Having received an information sheet about the study and not having expressed their opposition
- Able to read, write, and understand French
- Affiliated with the SS or equivalent
Exclusion Criteria for teachers :
\- Person specially protected by law